celecoxib has been researched along with ALS - Amyotrophic Lateral Sclerosis in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS)." | 9.12 | Trial of celecoxib in amyotrophic lateral sclerosis. ( Andreasson, KI; Cudkowicz, ME; Drachman, DB; Rothstein, JD; Schoenfeld, DA; Shefner, JM; Zhang, H, 2006) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 7.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers." | 5.69 | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023) |
| "To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS)." | 5.12 | Trial of celecoxib in amyotrophic lateral sclerosis. ( Andreasson, KI; Cudkowicz, ME; Drachman, DB; Rothstein, JD; Schoenfeld, DA; Shefner, JM; Zhang, H, 2006) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 3.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a rare neurodegenerative disease." | 2.45 | Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. ( Benatar, M; Kurent, J; Moore, DH, 2009) |
| "Celecoxib treatment significantly delayed the onset of weakness and weight loss and prolonged survival by 25%." | 1.31 | Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. ( Almer, G; Drachman, DB; Dykes-Hoberg, M; Frank, K; Przedborski, S; Rothstein, JD; Teismann, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Salomon-Zimri, S | 1 |
| Pushett, A | 2 |
| Russek-Blum, N | 2 |
| Van Eijk, RPA | 1 |
| Birman, N | 1 |
| Abramovich, B | 1 |
| Eitan, E | 1 |
| Elgrart, K | 1 |
| Beaulieu, D | 1 |
| Ennist, DL | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, JM | 4 |
| Drory, VE | 2 |
| Goldshtein, H | 1 |
| Muhire, A | 1 |
| Petel Légaré, V | 1 |
| Rotkopf, R | 1 |
| Peterson, RT | 1 |
| Armstrong, GAB | 1 |
| Xia, Q | 1 |
| Hu, Q | 1 |
| Wang, H | 1 |
| Yang, H | 1 |
| Gao, F | 1 |
| Ren, H | 1 |
| Chen, D | 1 |
| Fu, C | 1 |
| Zheng, L | 1 |
| Zhen, X | 1 |
| Ying, Z | 1 |
| Wang, G | 1 |
| Gordon, PH | 1 |
| Cheung, YK | 1 |
| Levin, B | 1 |
| Andrews, H | 1 |
| Doorish, C | 1 |
| Macarthur, RB | 1 |
| Montes, J | 1 |
| Bednarz, K | 1 |
| Florence, J | 1 |
| Rowin, J | 1 |
| Boylan, K | 1 |
| Mozaffar, T | 1 |
| Tandan, R | 1 |
| Mitsumoto, H | 1 |
| Kelvin, EA | 1 |
| Chapin, J | 1 |
| Bedlack, R | 1 |
| Rivner, M | 1 |
| McCluskey, LF | 1 |
| Pestronk, A | 1 |
| Graves, M | 1 |
| Sorenson, EJ | 1 |
| Barohn, RJ | 1 |
| Belsh, JM | 1 |
| Lou, JS | 1 |
| Levine, T | 1 |
| Saperstein, D | 1 |
| Miller, RG | 1 |
| Scelsa, SN | 1 |
| Benatar, M | 1 |
| Kurent, J | 1 |
| Moore, DH | 1 |
| Nefussy, B | 1 |
| Hirsch, J | 1 |
| Cudkowicz, ME | 3 |
| Drachman, DB | 2 |
| Frank, K | 1 |
| Dykes-Hoberg, M | 1 |
| Teismann, P | 1 |
| Almer, G | 1 |
| Przedborski, S | 1 |
| Rothstein, JD | 2 |
| Schoenfeld, DA | 1 |
| Zhang, H | 2 |
| Andreasson, KI | 1 |
| Schoenfeld, D | 1 |
| Jillapalli, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis[NCT02164253] | Phase 2 | 23 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Treatment for familial amyotrophic lateral sclerosis/motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Creatine; Fructos | 2009 |
3 trials available for celecoxib and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; | 2023 |
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Celecoxib; Creatine; Double-Blind Met | 2008 |
Trial of celecoxib in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dino | 2006 |
5 other studies available for celecoxib and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Celecoxib; Ciprofloxacin; Dis | 2020 |
Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia.
Topics: Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Celecoxib; Cell Death; Cell Line; Cyclooxygenase | 2015 |
Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Celecoxib; Disease Progression; Dyslipidemias; Female; Fructose | 2011 |
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2002 |
Revised statistical motor unit number estimation in the Celecoxib/ALS trial.
Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib | 2007 |